In the patent dispute over Betmiga PR (Mirabegron), an overactive bladder treatment with an annual prescription amount of ￦65 billion, generic companies won the first trial.

From the standpoint of generic companies, including Hanmi and Chong Kun Dang, which have already launched generics, and are about to release generics, the obstacles related to patents have disappeared. However, It is highly likely that the original company Astellas will choose to go to the Supreme Court.

◆Use patent·crystal patent invalidated

On the afternoon of the 22nd, the Patent Court of Korea ruled against the plaintiff (Astellas) in a lawsuit filed by Astellas against 11 companies includi